{"protocolSection": {"identificationModule": {"nctId": "NCT00995904", "orgStudyIdInfo": {"id": "MAP0020-CL-P201"}, "organization": {"fullName": "Allergan", "class": "INDUSTRY"}, "briefTitle": "Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma", "officialTitle": "A Randomized, Open-Label, 3-Dose, 3-Period, Crossover Phase 2 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-09"}, "primaryCompletionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-10-06", "studyFirstSubmitQcDate": "2009-10-14", "studyFirstPostDateStruct": {"date": "2009-10-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2013-04-17", "resultsFirstSubmitQcDate": "2013-10-28", "resultsFirstPostDateStruct": {"date": "2013-11-20", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-09", "lastUpdatePostDateStruct": {"date": "2014-01-09", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Allergan", "class": "INDUSTRY"}, "collaborators": [{"name": "MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation aerosol delivery."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthmatic children"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 25, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment A, then Treatment B, then Treatment C", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}, {"label": "Treatment A, then Treatment C, then Treatment B", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}, {"label": "Treatment B, then Treatment A, then Treatment C", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}, {"label": "Treatment B, then Treatment C, then Treatment A", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}, {"label": "Treatment C, then Treatment A, then Treatment B", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals.\n\nTreatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}, {"label": "Treatment C, then Treatment B, then Treatment A", "type": "EXPERIMENTAL", "description": "Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) at Visit 4", "interventionNames": ["Drug: 84ug MAP0020", "Drug: 42ug MAP0020", "Drug: 21ug MAP0020"]}], "interventions": [{"type": "DRUG", "name": "84ug MAP0020", "description": "84ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "armGroupLabels": ["Treatment A, then Treatment B, then Treatment C", "Treatment A, then Treatment C, then Treatment B", "Treatment B, then Treatment A, then Treatment C", "Treatment B, then Treatment C, then Treatment A", "Treatment C, then Treatment A, then Treatment B", "Treatment C, then Treatment B, then Treatment A"]}, {"type": "DRUG", "name": "42ug MAP0020", "description": "42ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "armGroupLabels": ["Treatment A, then Treatment B, then Treatment C", "Treatment A, then Treatment C, then Treatment B", "Treatment B, then Treatment A, then Treatment C", "Treatment B, then Treatment C, then Treatment A", "Treatment C, then Treatment A, then Treatment B", "Treatment C, then Treatment B, then Treatment A"]}, {"type": "DRUG", "name": "21ug MAP0020", "description": "21ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "armGroupLabels": ["Treatment A, then Treatment B, then Treatment C", "Treatment A, then Treatment C, then Treatment B", "Treatment B, then Treatment A, then Treatment C", "Treatment B, then Treatment C, then Treatment A", "Treatment C, then Treatment A, then Treatment B", "Treatment C, then Treatment B, then Treatment A"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cmax of Budesonide After Administration of MAP0020", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "timeFrame": "12 hours"}, {"measure": "AUC(0-inf) of Budesonide After Administration of MAP0020", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug to time infinity after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "timeFrame": "12 hours"}, {"measure": "Half-life (t1/2) of Budesonide After Administration of MAP0020", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "timeFrame": "12 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Male or female children with a documented diagnosis of mild-to-moderate persistent asthma (according to the 2007 NIH \\[EPR\\] criteria) for at least 1 year prior to screening and medically stable for a minimum of 6 months prior to screening.\n2. Children 4 through 11 years old (up to one day prior to their 12th birthday at randomization).\n3. Body weight \\>=45 lbs, body mass index (BMI) \\<=30 kg/m2\n4. ICS users had to have been taking an ICS for \\>=3 months and on a stable dose for \\>= 1 month before Visit 1.ICS users had to be stable enough and able to withhold their therapeutic ICS for 24 hours prior to study drug administration,\n5. Subjects already on stable immunotherapy (ie, allergy shots)if not anticipated to change during the study.\n\nKey Exclusion Criteria:\n\n1. Females of child-bearing potential/menarche.\n2. Diagnosis of any other significant chronic illness or abnormality.\n3. Use of corticosteroids", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "4 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Paul Ratner, MD", "affiliation": "Sylvana Research Associates", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Ammar Hatab, MD", "affiliation": "West Coast Clinical Trials LLC", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "West Coast Clinical Trials LLC", "city": "Cypress", "state": "California", "country": "United States", "geoPoint": {"lat": 33.81696, "lon": -118.03729}}, {"facility": "Sylvana Research Associates", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This is a 3-treatment, 3-period, 6-sequence crossover study. Each subject received all 3 treatments in a randomly assigned order: treatments A, B, and C, the sequences were ABC, ACB, BAC, BCA, CAB, and CBA.", "groups": [{"id": "FG000", "title": "Treatment A, Then Treatment B, Then Treatment C", "description": "Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}, {"id": "FG001", "title": "Treatment A, Then Treatment C, Then Treatment B", "description": "Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}, {"id": "FG002", "title": "Treatment B, Then Treatment A, Then Treatment C", "description": "Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}, {"id": "FG003", "title": "Treatment B, Then Treatment C, Then Treatment A", "description": "Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}, {"id": "FG004", "title": "Treatment C, Then Treatment A, Then Treatment B", "description": "Study visits were separated by 3-7 day intervals. Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}, {"id": "FG005", "title": "Treatment C, Then Treatment B, Then Treatment A", "description": "Study visits were separated by 3-7 day intervals. Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 3; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb\u00ae Go) at Visit 4"}], "periods": [{"title": "Visit 2 (Randomization)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Visit 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "comment": "One subject was withdrawn from the study after completion of Visit 2 but prior to Visit 3.", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Visit 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Follow-up Visit (Final Visit)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}, {"groupId": "FG004", "numSubjects": "5"}, {"groupId": "FG005", "numSubjects": "3"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Patients", "description": "All patients that were enrolled in the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "25"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.3", "spread": "1.88"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "11"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "14"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cmax of Budesonide After Administration of MAP0020", "description": "The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "21ug MAP0020", "description": "21ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG001", "title": "42ug MAP0020", "description": "42ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG002", "title": "84ug MAP0020", "description": "84ug of unit dose budesonide delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "92.5", "spread": "72.9"}, {"groupId": "OG001", "value": "175", "spread": "96.0"}, {"groupId": "OG002", "value": "370", "spread": "236"}]}]}]}, {"type": "PRIMARY", "title": "AUC(0-inf) of Budesonide After Administration of MAP0020", "description": "The AUC(0-inf) is the area under the plot of plasma concentration of drug to time infinity after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\\*min/ml).", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg*min/ml", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "21ug MAP0020", "description": "21ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG001", "title": "42ug MAP0020", "description": "42ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG002", "title": "84ug MAP0020", "description": "84ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3750", "spread": "1560"}, {"groupId": "OG001", "value": "8710", "spread": "3270"}, {"groupId": "OG002", "value": "19400", "spread": "8230"}]}]}]}, {"type": "PRIMARY", "title": "Half-life (t1/2) of Budesonide After Administration of MAP0020", "description": "Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes.", "populationDescription": "Patients with available data at specified time points are included in the analysis population.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "minutes", "timeFrame": "12 hours", "groups": [{"id": "OG000", "title": "21ug MAP0020", "description": "21ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG001", "title": "42ug MAP0020", "description": "42ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}, {"id": "OG002", "title": "84ug MAP0020", "description": "84ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}, {"groupId": "OG002", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.3", "spread": "31.2"}, {"groupId": "OG001", "value": "74.6", "spread": "29.8"}, {"groupId": "OG002", "value": "86.9", "spread": "29.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "All 25 subjects who received 21ug MAP0020, 24 subjects who received 42ug MAP0020, and 24 subjects who received 84ug MAP0020 are included in the adverse event analysis.", "eventGroups": [{"id": "EG000", "title": "21ug MAP0020", "description": "21ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 25, "otherNumAffected": 2, "otherNumAtRisk": 25}, {"id": "EG001", "title": "42ug MAP0020", "description": "42ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 1, "otherNumAtRisk": 24}, {"id": "EG002", "title": "84ug MAP0020", "description": "84ug of unit dose budesonide inhalation suspension delivered by Aeroneb\u00ae Go (MAP0020) as per protocol", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 0, "otherNumAtRisk": 24}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 25}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 24}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 24}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."}, "pointOfContact": {"title": "VP, Scientific Affairs", "organization": "MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan", "email": "dkellerman@mappharma.com", "phone": "650-386-3100"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21711", "name": "Budesonide", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}